Olomouc-based medtech startup Kardi Ai, which develops AI-powered technology for long-term heart rhythm monitoring, has raised €5.3 million in a Series A funding round led by German HealthTech investor Callisto Health, with participation from Seed Starter by Česká spořitelna and Slovenská sporiteľňa, BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels, as Vestbee was informed.
- Founded in 2022 by Tomáš Skála, Stephen Burke, Pavel Digaňa and David Skála, Kardi Ai combines an ECG-equipped chest strap, a mobile application and AI-powered analysis to monitor heart activity and flag potential cardiac arrhythmias. Its technology provides patients and physicians with data to support decisions about further medical care.
- In the Czech Republic, Kardi Ai works with more than 70 hospitals and over 20 corporate and employee-benefit partners, with its technology used by more than 6,000 people. The company has also established partnerships with healthcare providers in Slovakia.
- Kardi Ai is also developing predictive models to estimate the risk of cardiac arrhythmias. These models will require expert validation and regulatory approval before they can be used in clinical practice.
Details of the deal
- With the fresh capital, the company plans to expand across Europe and Asia and invest in predictive models designed to estimate the risk of cardiac arrhythmias based on multiple measurements.
- In Europe, Kardi Ai is preparing to enter the German market, building on its existing presence in Czechia, Poland, Slovakia, Romania and Bulgaria.
- Beyond Europe, the company plans to begin operations in India in the final quarter of 2026 and is preparing to enter the United Arab Emirates. It is also completing medical device approval in Singapore, which it plans to use as a gateway to Southeast Asia.
